FREMONT, Calif., Feb. 20 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc.
(PDL) (Nasdaq: PDLI) today announced that industry veteran Mark A.
McCamish, M.D., Ph.D. will join the company as senior vice president and
chief medical officer on February 21, 2007. The company also announced the
promotion of Richard Murray, Ph.D. to executive vice president and chief
scientific officer. Dr. Murray was also appointed to the company's board of
directors.
Dr. McCamish brings over 25 years of experience in corporate
management, clinical and pharmaceutical research, and academics to PDL's
senior management team. He will oversee all clinical development functions
and programs at the company, including regulatory affairs, safety, clinical
development, clinical operations and biometry/data management.
Dr. Murray joined PDL as vice president of research in April 2003 and
was named senior vice president and chief scientific and technical officer
in September 2005. In his new roles, Dr. Murray will continue to oversee
the company's antibody discovery, process sciences, manufacturing and
preclinical development activities, in addition to participating as a PDL
board member.
"With Mark joining our organization and Rich continuing to head our
research and development efforts, we now have stronger leadership in place
to support and drive the long-term growth of our development programs,"
said Mark McDade, chief executive officer, PDL BioPharma. "Mark's proven
track record in development at some of the healthcare industry's largest
and most successful organizations makes him an ideal choice to lead PDL's
exciting clinical programs focused on cancer, autoimmune and inflammatory
diseases and cardiovascular disorders. We believe his knowledge in the area
of pharmacogenomic profiling, based on his recent experience at Perlegen,
will aid the design of more informative and effective clinical trials at
PDL."
Dr. McCamish comes to PDL from Perlegen Sciences, where, since 2003, he
served as chief medical officer and vice president of clinical development
of the privately-held pharmacogenomics company focused on applying
personalized medicine technology to drug development.
Previously, he held various senior-level development positions at
Amgen, Inc., including responsibility for international development
activities and new product development strategies in various therapeutic
areas. Prior to his tenure at Amgen, Dr. McCamish held broad
responsibilities at Abbott Laboratories, including national and
international clinical research supporting the launch of multiple products,
interfacing with marketing and sales departments and competitive product
evaluation. Dr. McCamish also has years of experience in academia at Ohio
State University, the University of California at Davis and Michigan State
University.
About PDL BioPharma
PDL BioPharma, Inc. is a biopharmaceutical company focused on
discovering, developing and commercializing innovative therapies for severe
or life- threatening illnesses. Commercially focused in the acute-care
hospital setting, PDL markets and sells its portfolio of leading products
in the United States and Canada. A pioneer of antibody humanization
technology, PDL promotes this technology through licensing agreements and
clinical development of its own diverse pipeline of investigational
compounds. PDL's research platform centers on the discovery and development
of antibodies to treat cancer and autoimmune diseases. For more
information, please visit http://www.pdl.com.
NOTE: PDL BioPharma and the PDL BioPharma logo are considered
trademarks of PDL BioPharma, Inc.
SOURCE PDL BioPharma, Inc.
 back to top
Related links:
http://www.pdl.com/
CONTACT:
Ami Knoefler, Corporate and Investor
Relations, +1-510-284-8851, or ami.knoefler@pdl.com, or Jean
Suzuki, Corporate Relations, +1-510-574-1550, or
jean.suzuki@pdl.com, both of PDL BioPharma, Inc.
|
